SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): January 19, 2009 (January
22, 2009)
CHEMBIO
DIAGNOSTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
|
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
|
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
|
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01. REGULATION
FD DISCLOSURE.
On
January 19, 2009 Chembio granted, effective December 31, 2008, a limited
exclusive license within a defined field of application for Chembio’s Dual Path
Platform technology to Bio-Rad Laboratories, Inc. (“Bio-Rad”). The license
was granted following development milestones as set forth in the previously
announced agreement between Chembio and Bio-Rad in April 2008. That agreement
provides for the development by Chembio of a multiplex test employing Chembio's
patented DPP™ Dual Path Platform test system, which test also would employ
certain proprietary reagents belonging to Bio-Rad. As part of this
agreement, Chembio will receive $340,000 from Bio-Rad as a license
fee.
In
accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K is being furnished and shall not be deemed
“filed” for the purpose of Section 18 of the Securities Exchange Act of
1934, nor shall it be deemed incorporated by reference in any
filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: January
22,
2009 Chembio
Diagnostics, Inc.
By: /s/ Lawrence A.
Siebert
Lawrence
A. Siebert
Chief
Executive Officer